Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Novacyt launches IVDR-certified Yourgene Insight DPYD test in Europe
Novacyt has introduced the IVDR-certified Yourgene Insight DPYD test for the European market and can now commercially distribute it in regulated markets. The test detects 19 clinically relevant variants in the DPYD gene, including all current tier‑1 and tier‑2 variants, and according to the company is the first CE-marked DPYD test under the IVDR with this variant coverage. Novacyt developed the product with clinicians and previously offered the test in May 2026 as research-use-only. » More on de.investing.com
Novacyt achieves 18% revenue growth in first half of 2026
Novacyt reports H1 2026 revenue of £11.6m, an increase of 18% year on year. The instruments segment grew around 30% thanks to the LightBench Discover platform, while the clinical business rose by more than 20% driven by demand for non‑invasive prenatal tests and products for treating sickle cell disease. The acquisition of Southern Cross Diagnostics contributed £1.8m post‑acquisition; sales increased by over 30% in the Americas and by about 22% in Asia-Pacific. Novacyt is implementing a restructuring programme expected to deliver up to £4.0m in annual cost savings and anticipates IVDR approval for the DPYD kit in the coming months. » More on de.investing.com
Novacyt publishes annual report and financial statements for 2025
Novacyt has published its annual report and financial statements for the year ended 31 December 2025 and made them available on the company website. The company, which specializes in molecular diagnostics, reports on its three business divisions—clinical diagnostics, instrumentation and research use only—and highlights its global presence in more than 65 countries. Novacyt lists locations in Le Vésinet, Manchester, Singapore, the USA and Canada, and notes the acquisition of Southern Cross Diagnostics in Australia in March 2026. » More on de.investing.com
Novacyt schedules general meeting for 30 June and announces investor presentation
Novacyt will hold its annual general meeting on 30 June 2026 at 11:00 CEST at the Hilton Paris Charles de Gaulle. CEO Lyn Rees and CFO Steve Gibson will deliver an investor presentation on the day of the meeting via the Investor Meet Company platform; the presentation will have automatic French captions. Investors can register for the webinar through the platform; the following users will automatically receive an invitation. » More on de.investing.com
Novacyt: CSO Joanne Mason resigns with immediate effect
Novacyt said Dr. Joanne Mason is stepping down from her role as chief scientific officer and board member with immediate effect to pursue new professional opportunities. Mason served in the role for six years and helped shape the scientific direction and R&D foundations of the molecular diagnostics company. The company gave no information on a successor or further details. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 13.27m | 132.65% |
| Gross profit | 6.14m | 22.44% |
| Net profit | -6.65m | 78.95% |
| EBITDA | -4.46m | 73.39% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €37.7m |
Number of shares | 72.47m |
52-week high/low | €0.52 - €0.44 |
| Dividends | No |
Beta | 1.11 |
P/E ratio | -0.76 |
PEG ratio | -0.04 |
P/B ratio | 1.42 |
P/S ratio | 0.81 |
Company profile
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
| Name | Novacyt |
| CEO | Lyn Dafydd Rees |
| Headquarters | Le Vésinet,
if France |
| Website | |
| IPO | 12/10/2012 |
| Employees | 234 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | ALNOV.PA |
London Stock Exchange | NCYT.L |
Pnk | NVYTF |
Frankfurt | NYZ.F |
DĂĽsseldorf | NYZ.DU |
London | NCYT.L |
Paris | ALNOV.PA |
MĂĽnchen | NYZ.MU |